What should I know first?

Substances and medicines can sometimes produce a substantial change toward elevated, unusually expansive or intensely irritable mood. The clinical picture may resemble mania, but an induced disorder requires evidence linking it to the exposure or withdrawal and consideration of other explanations.

Feeling briefly energized, nervous or sleepless is not enough by itself. A person can experience an adverse reaction while taking medication correctly; the diagnosis does not imply misuse. Equally, a substance history should not cause clinicians to overlook an independent bipolar disorder.

The immediate priority is safety and an accurate assessment of the whole presentation.

Signs and Symptoms

Concerning changes can include markedly increased activity, reduced need for sleep, rapid speech, racing thoughts, unusual confidence, impulsive decisions or severe irritability. The person may feel productive or well while others notice that behaviour is unsafe or out of character.

Depressive symptoms may also be present, but they are not required to make a bipolar-related presentation important. Psychosis, dangerous behaviour, inability to care for basic needs or several nights of rapidly escalating activation warrant urgent assessment. Confusion, seizures or breathing difficulty suggest a possible medical emergency and should not be treated as merely a mood problem.

Assessment and UK terminology

Marked activation after a medicine change needs clinical assessment, including whether an independent bipolar condition better explains the course. MHRA recognises mania among possible systemic corticosteroid psychiatric reactions; the risk is not confined to misuse.

The clinician reconstructs the relationship between symptoms and substance use, medication initiation, dose changes or discontinuation. Evidence is needed that the exposure can plausibly produce the presentation. Prior episodes without exposure, family history and symptoms continuing beyond expected effects help evaluate an independent bipolar disorder.

A drug screen cannot answer every question, and an absent or positive result is not a diagnosis by itself. A medical examination may be necessary to investigate other causes. Diagnostic decisions can evolve during follow-up, but urgent treatment should not be delayed while clinicians work out whether the episode is induced or independent.

How Common Is It?

A single prevalence percentage would be misleading because this category covers different agents, exposure patterns and patient populations. Reports of insomnia or agitation are not equivalent to diagnosed induced bipolar-related disorder. Likewise, rates in emergency departments or specialist addiction services cannot automatically be applied to ordinary prescribed use.

No universal risk estimate is supplied here. For a particular medication, current product information and the patient's history are more relevant than a pooled claim about all drugs. Uncertainty about frequency is a reason for careful monitoring, not for dismissing a marked change in mood or behaviour.

What Causes It?

Potential explanations include direct substance effects, medication-related activation and withdrawal from an agent capable of producing such symptoms. Different exposures have different effects, and susceptibility varies. Sleep disruption, physical illness and an underlying bipolar vulnerability may contribute at the same time.

The label induced should not be used simply because exposure happened first; clinicians need a plausible relationship and a better fit than competing explanations. Physical dependence can develop during prescribed treatment and is not identical to addiction. A person should be able to describe every substance and medicine without fear that the information will be used to blame them.

What Do We Know About the Brain?

Substances can change alertness, sleep and systems involved in mood and behaviour, but there is no single brain mechanism shared by every induced bipolar-related presentation. Group research on primary bipolar disorder cannot establish that an individual adverse reaction represents the same lifelong condition.

Neither a brain scan nor a consumer chemical test settles the distinction. The course over time, the exposure and a careful clinical examination remain central. Detailed pharmacology is best understood medication by medication, without assuming that two agents with superficially similar effects have identical risks or withdrawal patterns.

Conditions With Similar Symptoms

Primary bipolar I or bipolar II disorder, intoxication, withdrawal, psychotic disorders, delirium and medically caused mood changes can overlap with the presentation. Feeling anxious or unable to sleep after starting a medicine does not necessarily amount to mania. Antidepressant-associated mood elevation particularly requires careful assessment: a full syndrome that persists beyond the expected treatment effect can support an independent bipolar diagnosis rather than an induced one.

This is a clinical judgement, not a rule to apply by counting days at home. New severe symptoms need assessment even when the person already has a psychiatric diagnosis.

Other Conditions That Can Occur Together

Substance use disorder may be present, but it is not required. A person may instead have a prescribed treatment for another illness, an independent anxiety disorder or a pre-existing bipolar condition worsened by an exposure. Distinguishing these possibilities matters because treatment needs can differ.

The underlying condition for which medication was prescribed still requires care, even if that medication is suspected of contributing to the episode. Coordination between prescribers reduces the risk of conflicting changes. With permission, trusted people may help provide a clearer timeline when the affected person has limited insight into the change.

Treatment and support in the United Kingdom

Safety and review of the suspected exposure take priority. Treatment must account for the illness the medicine was treating, rather than abandon that care. Significant activation, unsafe behaviour or psychosis warrants urgent assessment.

Care begins with assessing safety and the need for urgent medical or psychiatric treatment. The suspected agent and the condition it was intended to treat must both be reviewed. A clinician may recommend a supervised medication change, treatment of withdrawal or care for the acute mood symptoms.

The approach depends on the exposure and severity; it is not simply stop everything and wait. Support for sleep, a lower-stimulation environment and practical protection from unsafe decisions can accompany professional care. Severe activation, psychosis or inability to remain safe may require a higher level of treatment.

Can medication help?

A prescriber decides how to manage the responsible medicine and whether symptom treatment is needed. Corticosteroid withdrawal can itself be hazardous; do not use this article as instructions for an abrupt stop.

What to Expect Over Time

Some episodes improve after the responsible exposure is safely addressed, while others require continuing treatment and diagnostic reassessment. Persistent symptoms can indicate a longer-lasting reaction, an independent disorder or another medical cause. The label should remain open to revision as evidence accumulates.

Recovery also involves addressing consequences such as disrupted work, financial decisions or strained relationships without treating those consequences as the person's identity. A clear record of the suspected reaction can inform future prescribing. Deliberate re-exposure to prove causation is not an appropriate home experiment.

Everyday Life and Support

Bring a complete list of medicines, supplements and substances, with dates of recent changes, to the assessment. It can help to record sleep and major behaviour changes rather than relying only on a description of feeling high or low. Trusted supporters can offer transport, help communicate concerns and assist with a safety plan, while respecting the person's dignity.

Do not drive or make major risky decisions when judgement is impaired. If there is immediate danger, psychosis, severe confusion, seizures or an inability to stay safe, seek emergency help rather than waiting for the suspected drug to wear off.

History

DSM-IV used broader substance-induced mood disorder terminology. DSM-5 separated bipolar-related and depressive presentations when the larger mood-disorders grouping was divided. The APA explains that DSM-5-TR then clarified wording so the bipolar-related category would not be misunderstood as requiring depression or as allowing depression alone to establish it.

The revision also made clearer that medication-related symptoms can arise during use or in a withdrawal context. ICD-11 uses substance-specific mood-disorder categories with symptom qualifiers rather than precisely the same organizational structure. Historical labels therefore should not be converted mechanically.

These changes reflect an effort to distinguish the nature of the mood disturbance and its likely cause, while avoiding an automatic lifelong bipolar label after any unusual reaction to a medicine.

Sources and References

  1. DSM-5-TR: Substance/Medication-Induced Bipolar and Related Disorder

    Scope: International scientific/educational source; not used as UK prescribing, regulatory or service authority.

  2. Clinical descriptions and diagnostic requirements for ICD-11: substance-induced mood disorders and bipolar boundaries

    Scope: International scientific/educational source; not used as UK prescribing, regulatory or service authority.

  3. Bipolar Disorder

    Scope: International scientific/educational source; not used as UK prescribing, regulatory or service authority.

  4. Benzodiazepine safety communication: severe withdrawal reactions

    Scope: International scientific/educational source; not used as UK prescribing, regulatory or service authority.

  5. Corticosteroids: early psychiatric side-effects

    Scope: United Kingdom medicines safety.

  6. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top